Clinical Trials

CNSOther hematologic neoplasm

58 enrolled

Neurofibromatosis 1, Leukemia, Myelomonocytic, Juvenile

NCT05038592 2026-04-14

Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes

Phase 1/2 Active not recruiting

64 enrolled

Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

NCT04049539 2026-04-08

Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction

28 enrolled

Leukemia, Myeloid, Acute

NCT06481735 2026-03-16

TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL

30 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03661307 2026-01-12

Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

73 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04128748 2025-12-17

Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

52 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04707300 2025-11-20

HTLP-ONCO

10 enrolled

Leukemia, Myeloid, Acute, Neoplasm, Residual, Hematologic Neoplasms

NCT06928662 2025-11-06

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

36 enrolled

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT07008885 2025-06-25

BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL

30 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02257138 2025-06-08

Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia

Phase 1/2 Completed

30 enrolled 14 charts

Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases

NCT06376721 2024-04-19

Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma

43 enrolled

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04793399 2024-03-19

Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients

Phase 1/2 Terminated

9 enrolled 7 charts

Leukemia, Myeloid, Chronic-Phase

NCT05320380 2023-09-01

A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat

Phase 1/2 Withdrawn

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04493099 2020-11-12

Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML

Phase 1/2 Withdrawn

Leukemia, Myeloid, Acute

NCT02921061 2020-03-17

Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS

Phase 1/2 Completed

28 enrolled 13 charts

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT01729845 2019-02-07

Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Phase 1/2 Completed

52 enrolled 9 charts

Leukemia, Myeloid, Acute

NCT00129558 2013-12-04

A Study to Evaluate PT-523 in Patients With Refractory Leukemia

Phase 1/2 Withdrawn